Mr. Dimitri Eynikel:

I will respond to the point on China. When it comes to the mRNA technologies, it is quite interesting that the example of China is used, because one of the only agreements BioNTech has to voluntarily share its technology is with Fosun in China. I do not know where this threat or risk from China suddenly comes from if BioNTech actually shares its technology with a Chinese company. China is, by the way, one of the only countries that has the ability to lift and get access to trade secrets out of public interest. BioNTech did it voluntarily despite that risk being there. It does not jeopardise any voluntary agreement. That is the first aspect on China.

The second aspect is that China is not happy with being forced out of the Quad text because that is what it actually entails. China is forced out of using that text but it has said that it is not interested in using it. Lately, it has been commenting that it voluntary wants to opt out of using that text, will say it is not interested in the use of the text and will form a licence as well. The issue of China is not at all a serious concern for us in that respect. However, we support the idea that any country that wants to use this text, or the waiver that will potentially come at the end of the process, should have the text available to it because any country is at risk of the pandemic. It is of shared interest to have this option available.